An algorithm for diagnosis and treatment of refractory GERD

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 6, 2010, Pages 923-936

  Hershcovici, Tiberiu ^a,b   Fass, Ronnie ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Gastro esophageal reflux disease (GERD); Heartburn; Proton pump Inhibitors (PPIs); Refractory GERD

Indexed keywords

ADX 10059; ARBACLOFEN PLACARBIL; BACLOFEN; BOTULINUM TOXIN; ESOMEPRAZOLE; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LESOGABERAN; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; XP 19986;

ACUPUNCTURE; ADD ON THERAPY; ALTERNATIVE MEDICINE; ANTIREFLUX OPERATION; ANXIETY DISORDER; BEDTIME DOSAGE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENDOSCOPY; EPIGASTRIC PAIN; ESOPHAGEAL PH MONITORING; ESOPHAGUS PAIN; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; IMPEDANCE; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; LOWER ESOPHAGUS SPHINCTER; PATIENT CARE; PATIENT COMPLIANCE; PSYCHOTHERAPY; REFLUX ESOPHAGITIS; REVIEW; SMOOTH MUSCLE RELAXATION; SOMNOLENCE; STOMACH FUNDOPLICATION; STOMACH PARESIS; STOMACH PH; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; VISCERAL PAIN; WEAKNESS;

EID: 78649746239     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2010.10.004     Document Type: Article

References (80)

1. J.M. Inadomi, L. McIntyre, L. Bernard, and A.M. Fendrick Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs Am J Gastroenterol 98 2003 1940 1944
2. Gallup Organization The 2000 Gallup study of consumers' use of stomach relief products 2000 Gallup Organization Princeton
3. B.B. Dean, A.D. Gano Jr., K. Knight, J.J. Ofman, and R. Fass Effectiveness of proton pump inhibitors in nonerosive reflux disease Clin Gastroenterol Hepatol 2 2004 656 664 (Pubitemid 39013424)
4. W.D. Chey, R.R. Mody, E.Q. Wu, L. Chen, S. Kothari, and B. Persson Treatment patterns and symptom control in patients with GERD: US community-based survey Curr Med Res Opin 25 2009 1869 1878
5. R. Fass, and R.E. Sampliner Barrett's oesophagus: optimal strategies for prevention and treatment Drugs 63 2003 555 564
6. R. Fass, and D. Sifrim Management of heartburn not responding to proton pump inhibitors Gut 58 2009 295 309
7. Rome III The functional gastrointestinal disorders 3rd ed. 2006 Degnon Associates, Inc. Mc Lean, VA
8. R. Fass Persistent heartburn in a patient on proton-pump inhibitor Clin Gastroenterol Hepatol 6 2008 393 400
9. R. Fass, and A. Gasiorowska Refractory GERD: what is it? Curr Gastroenterol Rep 10 2008 252 257
10. A.P. Hungin, G. Rubin, and H. O'Flanagan Factors influencing compliance in long-term proton pump inhibitor therapy in general practice Br J Gen Pract 49 1999 463 464
11. N.T. Gunaratnam, T.P. Jessup, J. Inadomi, and D.P. Lascewski Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease Aliment Pharmacol Ther 23 2006 1473 1477
12. R. Tutuian, M.F. Vela, E.G. Hill, I. Mainie, A. Agrawal, and D.O. Castell Characteristics of symptomatic reflux episodes on acid suppressive therapy Am J Gastroenterol 103 2008 1090 1096
13. F. Zerbib, A. Duriez, S. Roman, M. Capdepont, and F. Mion Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors Gut 57 2008 156 160
14. G. Karamanolis, W. Stevens, R. Vos, J. Tack, P. Clave, and D. Sifrim Oesophageal tone and sensation in the transition zone between proximal striated and distal smooth muscle oesophagus Neurogastroenterol Motil 20 2008 291 297
15. D.R. Lichtenstein, B.D. Cash, R. Davila, T.H. Baron, D.G. Adler, and M.A. Anderson Role of endoscopy in the management of GERD Gastrointest Endosc 66 2007 219 224
16. C.H. Poh, A. Gasiorowska, T. Navarro-Rodriguez, M.R. Willis, D. Hargadon, and N. Noelck Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment Gastrointest Endosc 71 2010 28 34
17. D.J. Hetzel, J. Dent, W.D. Reed, F.M. Narielvala, M. Mackinnon, and J.H. McCarthy Healing and relapse of severe peptic esophagitis after treatment with omeprazole Gastroenterology 95 1988 903 912
18. S.J. Sontag, B.I. Hirschowitz, S. Holt, M.G. Robinson, J. Behar, and M.M. Berensen Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study Gastroenterology 102 1992 109 118
19. J.E. Richter How to manage refractory GERD Nat Clin Pract Gastroenterol Hepatol 4 2007 658 664
20. J. Dent Microscopic esophageal mucosal injury in nonerosive reflux disease Clin Gastroenterol Hepatol 5 2007 4 16
21. J.M. Bautista, W.M. Wong, G. Pulliam, R.F. Esquivel, and R. Fass The value of ambulatory 24 h esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications Dig Dis Sci 50 2005 1909 1915
22. I. Hirano, J.E. Richter Practice Parameters Committee of the American College of Gastroenterology ACG practice guidelines: esophageal reflux testing Am J Gastroenterol 102 2007 668 685
23. B. Kuo, and D.O. Castell Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls Am J Gastroenterol 91 1996 1532 1538
24. R. Fass, R. Hell, R.E. Sampliner, G. Pulliam, E. Graver, and V. Hartz Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities Dig Dis Sci 44 1999 2263 2269
25. S. Charbel, F. Khandwala, and M.F. Vaezi The role of esophageal pH monitoring in symptomatic patients on PPI therapy Am J Gastroenterol 100 2005 283 289
26. G. Karamanolis, T. Vanuytsel, D. Sifrim, R. Bisschops, J. Arts, and P. Caenepeel Yield of 24-hour esophageal pH and Bilitec monitoring in patients with persisting symptoms on PPI therapy 53 2008 2387 2393
27. G.H. Koek, J. Tack, D. Sifrim, T. Lerut, and J. Janssens The role of acid and duodenal gastroesophageal reflux in symptomatic GERD Am J Gastroenterol 96 2001 2033 2040
28. I. Mainie, R. Tutuian, S. Shay, M. Vela, X. Zhang, and D. Sifrim Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring Gut 55 2006 1398 1402
29. N. Sharma, A. Agrawal, J. Freeman, M.F. Vela, and D. Castell An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring Clin Gastroenterol Hepatol 6 2008 521 524
30. I. Hirano, X. Zhang, J.E. Pandolfino, and P. Kahrilas Bravo pH capsule monitoring with and without proton pump inhibitor therapy Clin Gastroenterol Hepatol 3 2005 1083 1088
31. D. Sifrim, D.O. Castell, J. Dent, and P.J. Kahrilas Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux Gut 53 2004 1024 1031
32. M.F. Vela, L. Camacho-Lobato, R. Srinivasan, R. Tutuian, P.O. Katz, and D.O. Castell Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole Gastroenterology 120 2001 1599 1606
33. P. Katz, R.M. Gideon, and R. Tutuian Reflux symptoms on twice daily (BID) proton pump inhibitor (PPI) associated with non acid reflux; a manifestation of hypersensitive esophagus? Am J Gastroenterol 128 #925 2005 A-130 (abstract)
34. F. Zerbib, S. Roman, A. Ropert, S.B. des Varannes, P. Pouderoux, and U. Chaput Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy Am J Gastroenterol 101 2006 1956 1963
35. F. Pace, O. Sangaletti, S. Pallotta, P. Molteni, and G.B. Porro Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring Scand J Gastroenterol 42 2007 1031 1039
36. A. Siddiqui, S. Rodriguez-Stanley, S. Zubaidi, and P.B. Miner Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects Dig Dis Sci 50 2005 81 85
37. R. Farre, M.H. Van Malenstein, R. de Vos, K. Geboes, P. Vanden Berghe, and J. Tack Weakly acidic solutions containing pepsin and bile acids can increase significantly esophageal mucosa permeability Gastroenterology 132 #S1897 2007 A-274 (abstract)
38. J. Tack, G. Koek, I. Demedts, D. Sifrim, and J. Janssens Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 99 2004 981 988
39. A. Gasiorowska, T. Navarro-Rodriguez, C. Wendel, E. Krupinski, Z.H. Perry, and K. Koenig Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily Am J Gastroenterol 104 2009 2005 2013
40. G. Champion, J.E. Richter, M.F. Vaezi, S. Singh, and R. Alexander Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus Gastroenterology 107 1994 747 754
41. P. Netzer, A. Gut, R. Brundler, C. Gaia, F. Halter, and W. Inauen Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects Aliment Pharmacol Ther 15 2001 1375 1384
42. J.A. Todd, K.K. Basu, and J.S. de Caestecker Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus Aliment Pharmacol Ther 21 2005 969 975
43. G.H. Koek, D. Sifrim, T. Lerut, J. Janssens, and J. Tack Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro- oesophageal reflux refractory to proton pump inhibitors Gut 52 2003 1397 1402
44. R. Fass Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure Drugs 67 2007 1521 1530
45. T. Kaltenbach, S. Crockett, and L.B. Gerson Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach Arch Intern Med 166 2006 965 971
46. P.L. Peghini, P.O. Katz, and D.O. Castell Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects Gastroenterology 115 1998 1335 1339
47. W.K. Fackler, T.M. Ours, M.F. Vaezi, and J.E. Richter Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough Gastroenterology 122 2002 625 632
48. I. Mainie, R. Tutuian, and D.O. Castell Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough J Clin Gastroenterol 42 2008 676 679
49. A. Rackoff, A. Agrawal, I. Hila, I. Mainie, R. Tutuian, and D.O. Castell Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy Dis Esophagus 18 2005 370 373
50. P.J. Kahrilas, N.J. Shaheen, M.F. Vaezi, S.W. Hiltz, E. Black, and I.M. Modlin American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease Gastroenterology 135 2008 1383 1391 91 e1-e5
51. M. Khan, J. Santana, C. Donnellan, C. Preston, and P. Moayyedi Medical treatments in the short term management of reflux oesophagitis Cochrane Database Syst Rev 2007 CD003244
52. R. Fass, S.J. Sontag, B. Traxler, and M. Sostek Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial Clin Gastroenterol Hepatol 4 2006 40 56
53. J. Hatlebakk, P. Katz, B. Kuo, and D.O. Castell Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily Aliment Pharmacol Ther 12 1998 1235 1240
54. M. Frazzoni, M. Manno, E. De Micheli, and V. Savarino Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors Dig Liver Dis 39 2007 415 421
55. T. Shimatani, M. Moriwaki, J. Xu, S. Tazuma, and M. Inoue Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers Dig Liver Dis 38 2006 802 808
56. P. Sharma, N.J. Shaheen, M.C. Perez, B.L. Pilmer, M. Lee, and S.N. Atkinson Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies Aliment Pharmacol Ther 29 2009 731 741
57. R. Fass, W.D. Chey, S.F. Zakko, N. Andhivarothai, R.N. Palmer, and M.C. Perez Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease Aliment Pharmacol Ther 29 2009 1261 1272
58. L.A. Blackshaw Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain- gastroesophageal axis Am J Physiol 281 2001 G311 G315
59. C.L. Frisby, J.P. Mattsson, J.M. Jensen, A. Lehmann, J. Dent, and L.A. Blackshaw Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands Gastroenterology 129 2005 995 1004 (Pubitemid 41242690)
60. Q. Zhang, A. Lehmann, R. Ridga, J. Dent, and R.H. Holloway Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease Gut 50 2002 19 24
61. I. Lidums, A. Lehmann, H. Checklin, J. Dent, and R.H. Holloway Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects Gastroenterology 118 2000 7 13
62. T.I. Omari, M.A. Benninga, L. Sansom, R.N. Butler, J. Dent, and G.P. Davidson Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial J Pediatr 149 2006 436 438
63. M.F. Vela, R. Tutuian, P.O. Katz, and D.O. Castell Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH Aliment Pharmacol Ther 17 2003 243 251
64. R. Lal, J. Sukbuntherng, E.H. Tai, S. Upadhyay, F. Yao, and M.S. Warren Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen J Pharmacol Exp Ther 330 2009 911 921
65. L.B. Gerson, F.J. Huff, A. Hila, W.K. Hirota, S. Reilley, and A. Agrawal Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease Am J Gastroenterol 2009
66. G.E. Boeckxstaens, H. Beaumont, V. Mertens, H. Denison, M. Ruth, and J. Adler Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease Gastroenterology 139 2010 409 417
67. G.E. Boeckxstaens, H. Beaumont, J.G. Hatlebakk, D.G. Silberg, J. Adler, and H. Denison Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy Gastroenterology 136 2009 A436-A
68. C. Keywood, M. Wakefield, and J. Tack A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease Gut 58 2009 1192 1199
69. R. Fass, M. Shapiro, R. Dekel, and J. Sewell Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22 2005 79 94
70. M. Handa, K. Mine, H. Yamamoto, H. Hayashi, O. Tsuchida, and F. Kanazawa Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach J Clin Gastroenterol 28 1999 228 232
71. R.E. Clouse, P.J. Lustman, T.C. Eckert, D.M. Ferney, and L.S. Griffith Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial Gastroenterology 92 1987 1027 1036
72. S.A. Mirbagheri, A. Sadeghi, M. Amouie, S. Mansouri, M. Forootan, and A. Rashidi Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report Dig Dis Sci 53 2008 2621 2626
73. M.Q. Bromer, F. Friedenberg, L.S. Miller, R.S. Fisher, K. Swartz, and H.P. Parkman Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis Gastrointest Endosc 61 2005 833 839
74. R. Rosenthal, R. Peterli, M.O. Guenin, M. van Flüe, and C. Ackermann Laparoscopic antireflux surgery: long-term outcomes and quality of life J Laparosc Adv Surg Tech A 16 2006 557 561
75. I. Mainie, R. Tutuian, A. Agrawal, D. Adams, and D.O. Castell Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication Br J Surg 93 2006 1483 1487
76. V. Becker, M. Bajbouj, K. Waller, R.M. Schmid, and A. Meining Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy Aliment Pharmacol Ther 26 2007 1355 1360
77. G. del Genio, S. Tolone, F. del Genio, R. Aggarwal, A. d'Alessandro, and A. Allaria Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring J Gastrointest Surg 12 2008 1491 1496
78. R. Dickman, E. Schiff, A. Holland, C. Wright, S.R. Sarela, and B. Han Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn Aliment Pharmacol Ther 26 2007 1333 1344
79. J.H. Rubenstein, B. Nojkov, S. Korsnes, S.A. Adlis, M.J. Shaw, and B. Weinman Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome Aliment Pharmacol Ther 26 2007 443 453
80. B. Nojkov, J.H. Rubenstein, S.A. Adlis, M.J. Shaw, R. Saad, and J. Rai The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease Aliment Pharmacol Ther 27 2008 473 482